Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1/2 4Phase 1 3Phase NA 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1Dermatologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 2Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Transurethral Resection of Bladder × 1 year × Clear all
NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

University of California, San Francisco

Phase 1/2 Recruiting
47 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡